Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesAnakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure
Joint, Bone, Spine, 04/23/09
Announ N et al. - The authors describe the case of a 71-year-old man with recurrent pseudogout attacks affecting multiple joints. He had end-stage renal failure that contra-indicated the use of non-steroidal anti-inflammatory drugs and was resistant to therapy with glucocorticoids. Based on the recent findings that interleukin (IL)-1-beta is involved in crystal-induced inflammation, the patient received anakinra, a specific IL-1 inhibitor, in order to treat an acute attack of pseudogout.
Today in Gout and Hyperuricemia...keeping you current
Receive free subspecialty "5-minute updates" via email
The modern management of gout
Rheumatology, 10/08/09
Tophaceous gout: an unusual cause of multiple fractures
Scandinavian Journal of Rheumatology , 10/16/09
Melanocortin peptides inhibit urate crystal-induced activation of phagocytic cells
Arthritis Research & Therapy, 10/12/09
Sponsor
Article Search
Sponsor